Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Monopar gets rights to Onxeo's Validive

Chris Lieu
November 2, 2017 5:13 AM UTC

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) granted Monopar Therapeutics Inc. (Northbrook, Ill.) exclusive, worldwide rights to Validive clonidine lauriad (BA-028). Onxeo will receive a $1 million license fee and is eligible for $108 million in milestones, including $15.5 million for regulatory milestones. Onxeo is also eligible for royalties up to double digits...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Monopar Therapeutics Inc.

Onxeo S.A.